Interestingly, EGFR wild‐type NSCLC tumors have higher levels of PD‐L1 and tumor infiltrating lymphocytes, and respond better to PD‐1/PD‐L1‐targeted therapy compared with EGFR mutant NSCLC 1, 2. This evidence concerns the gene CD274 and neoplasm.